Successful treatment with defibrotide for sinusoidal obstruction syndrome after hematopoietic stem cell transplantation

Kimikazu Yakushijin, Toshimitsu Matsui, Atsuo Okamura, Katsuya Yamamoto, Mitsuhiro Ito, Kazuo Chihara

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Sinusoidal obstruction syndrome (SOS) (formerly known as hepatic veno-occlusive disease (VOD)) is a life-threatening complication subsequent to hematopoietic stem cell transplantation. However, no completely satisfactory strategies for the treatment of SOS have been established yet. Defibrotide is a single-stranded polydeoxyribonucleotide with anti-thrombotic, anti-ischemic, anti-inflammatory and thrombolytic properties, but without systemic anticoagulant effects, and some encouraging results have been reported in western countries. We treated four patients with defibrotide for SOS, since there seemed to be no possibility to cure the patients with conventionally available treatments in Japan. All patients showed evidence of multiple organ failure at the start of the treatment. Defibrotide was administered intravenously in normal saline in four divided doses for 14 to 27 days. Three patients (75%) responded to the therapy, while one died of SOS and cytomegalovirus infection despite intensive therapy. None of the patients suffered from significant adverse effects such as severe hemorrhage. This is the first report dealing with the treatment with defibrotide of Japanese patients with SOS. Because defibrotide is considered to be promising for the treatment of SOS, it is important to start a phase II study as soon as possible.

Original languageEnglish
Pages (from-to)55-65
Number of pages11
JournalKobe Journal of Medical Sciences
Issue number4
StatePublished - 2005
Externally publishedYes


  • Defibrotide
  • Hematopoietic stem cell transplantation
  • Sinusoidal obstruction syndrome
  • Veno-occlusive disease


Dive into the research topics of 'Successful treatment with defibrotide for sinusoidal obstruction syndrome after hematopoietic stem cell transplantation'. Together they form a unique fingerprint.

Cite this